Clinical Trial Update: A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Cadonilimab (AK104) in combination with standard treatment for function preservation in urinary tract cancers; the trial status is not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Tract Cancer

Drugs mentioned

• Cadonilimab (AK104) (Cadonilimab)

Snippet

Sponsor: Tongji Hospital | Conditions: Urinary System Tumor | Phase 2 | Status: NOT_YET_RECRUITING